Abstract 621P
Background
Durvalumab consolidation following chemoradiotherapy (CRT) is the standard treatment for patients with locally advanced non-small cell lung cancer. We have already reported the efficacy of biweekly carboplatin with nab-paclitaxel CRT. Here, we report the efficacy and tolerability of biweekly carboplatin with nab-paclitaxel CRT followed by durvalumab consolidation in real world practice in young and elderly groups.
Methods
We conducted a two-center retrospective cohort study. The study compared patients aged over 75 years with younger patients who recieved biweekly carboplatin with nab-paclitaxel chemoradiotherapy between 1 April 2018 and 31 March 2022.
Results
A total of 75 patients were enrolled: median age 70 (range, 55-85) years; over 75 years, 23 patients; younger, 52 patients; ECOG PS 0-1, 67; PS≧2, 8; stage II, 10; stage III, 65. Conversion to durvalumab therapy in the younger group was 92.3% (48/52) and 78.3% (18/23) in the older group. While all of the younger patients received consolidation therapy, three patients in the elderly group did not due to poor PS. Progression free survival (PFS) from CRT was 17.3 months (95%CI: 12.5-32.5 months) in the younger group and 11.7 months (95%CI: 6.2-19.9 months) in the older group(p=0.17). Median overall survival (OS) was 37.8 months (95%CI: 26.3-43.3 months) and 29.1 months (95%CI: 14.0-47.8 months), respectively (p=0.24). Two-year OS rate was 72.9% and 60.9%, respectively. Completion of consolidation therapy was 43.8% and 33.3. Grade3 or higher pneumonia was 14.6% and 5.5%.
Conclusions
Between the elderly and younger group, CRT with biweekly carboplatin and nab-paclitaxel, followed by durvalumab consolidation did not significantly differ in PFS and OS. On the other hand, the transition and completion rate of consolidation therapy was lower in elderly than in the younger group. In the elderly group, some patients could not proceed to or complete consolidation therapy due to the poor PS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Author.
Funding
Has not received any funding.
Disclosure
H. Tanaka: Financial Interests, Personal, Speaker’s Bureau: Ono Pharmaceutical Co. Ltd., Bristol Myers Squibb, AstraZeneca, Chugai Pharmaceutical Co, Boehringer-Ingelheim Japan Inc, Pfizer Japan Inc, Takeda, Bristol Meyers Squibb, Amgen . All other authors have declared no conflicts of interest.